Steven Cohen Ultragenyx Pharmaceutical Inc. Transaction History

Point72 Asset Management, L.P.

$36 Billion
Q2 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 539,749 shares of RARE stock, worth $27.2 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

539,749

Previous 539,749 -0.0%

Holding current value

$27.2 Million

Previous $22.2 Million -0.0%

% of portfolio

0.06%

Previous 0.06%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$37.42 - $51.61 $17.9 Million - $24.7 Million	478,849 Added 786.29%	539,749 $22.2 Million
Q1 2024 May 15, 2024	SELL	$43.02 - $53.69 $1.79 Million - $2.23 Million	-41,600 Reduced 40.59%	60,900 $2.84 Million
Q4 2023 Feb 14, 2024	SELL	$31.73 - $49.19 $19.5 Million - $30.2 Million	-613,962 Reduced 85.69%	102,500 $4.9 Million
Q3 2023 Nov 14, 2023	BUY	$34.92 - $46.66 $10.2 Million - $13.6 Million	291,588 Added 68.63%	716,462 $25.5 Million
Q2 2023 Aug 14, 2023	SELL	$37.35 - $52.15 $35.9 Million - $50.2 Million	-961,987 Reduced 69.36%	424,874 $19.6 Million
Q1 2023 May 15, 2023	BUY	$36.99 - $48.71 $24.4 Million - $32.1 Million	659,174 Added 90.58%	1,386,861 $55.6 Million
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $12.7 Million - $17.5 Million	377,000 Added 107.5%	727,687 $33.7 Million
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $3.08 Million - $5.1 Million	77,172 Added 28.21%	350,687 $14.5 Million
Q2 2022 Aug 15, 2022	SELL	$45.8 - $85.4 $2.06 Million - $3.84 Million	-44,982 Reduced 14.12%	273,515 $16.3 Million
Q1 2022 May 16, 2022	SELL	$62.2 - $84.4 $6.68 Million - $9.06 Million	-107,377 Reduced 25.21%	318,497 $23.1 Million
Q4 2021 Feb 14, 2022	BUY	$73.71 - $87.86 $6.3 Million - $7.51 Million	85,500 Added 25.12%	425,874 $35.8 Million
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $28.6 Million - $37.6 Million	-366,926 Reduced 51.88%	340,374 $30.7 Million
Q2 2021 Aug 16, 2021	BUY	$92.19 - $115.71 $54.2 Million - $68 Million	587,700 Added 491.39%	707,300 $67.4 Million
Q1 2021 May 17, 2021	SELL	$106.9 - $167.73 $10,690 - $16,773	-100 Reduced 0.08%	119,600 $13.6 Million
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $10.1 Million - $21.2 Million	119,700 New	119,700 $16.6 Million
Q1 2020 May 15, 2020	SELL	$33.8 - $62.9 $3.97 Million - $7.39 Million	-117,496 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$36.08 - $45.83 $2.23 Million - $2.83 Million	61,680 Added 110.51%	117,496 $5.02 Million
Q3 2019 Nov 15, 2019	BUY	$42.5 - $63.11 $916,002 - $1.36 Million	21,553 Added 62.9%	55,816 $2.39 Million
Q2 2019 Aug 14, 2019	BUY	$54.93 - $74.36 $1.88 Million - $2.55 Million	34,263 New	34,263 $2.18 Million
Q1 2019 May 15, 2019	SELL	$39.87 - $69.36 $6.93 Million - $12 Million	-173,700 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$38.89 - $77.3 $5.39 Million - $10.7 Million	138,700 Added 396.29%	173,700 $7.55 Million
Q3 2018 Nov 14, 2018	SELL	$71.81 - $90.15 $1.8 Million - $2.25 Million	-25,000 Reduced 41.67%	35,000 $2.67 Million
Q2 2018 Aug 14, 2018	SELL	$48.54 - $85.31 $485,400 - $853,100	-10,000 Reduced 14.29%	60,000 $4.61 Million
Q1 2018 May 15, 2018	SELL	$44.33 - $58.52 $1.04 Million - $1.37 Million	-23,400 Reduced 25.05%	70,000 $3.57 Million
Q4 2017 Feb 14, 2018	BUY	$43.54 - $57.32 $1.89 Million - $2.49 Million	43,400 Added 86.8%	93,400 $4.33 Million
Q3 2017 Nov 14, 2017	BUY	$49.79 - $66.32 $2.49 Million - $3.32 Million	50,000	50,000 $2.66 Million

Others Institutions Holding RARE

# of Institutions

292

Shares Held

88.4M

Call Options Held

535K

Put Options Held

198K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.53B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account